417 related articles for article (PubMed ID: 33321259)
41. Ghrelin and growth hormone (GH) secretagogue receptor (GHSR) mRNA expression in human pituitary adenomas.
Kim K; Arai K; Sanno N; Osamura RY; Teramoto A; Shibasaki T
Clin Endocrinol (Oxf); 2001 Jun; 54(6):759-68. PubMed ID: 11422110
[TBL] [Abstract][Full Text] [Related]
42. Technical advances in proteomics mass spectrometry: identification of post-translational modifications.
Amoresano A; Carpentieri A; Giangrande C; Palmese A; Chiappetta G; Marino G; Pucci P
Clin Chem Lab Med; 2009; 47(6):647-65. PubMed ID: 19426139
[TBL] [Abstract][Full Text] [Related]
43. Proteoforms and Proteoform Families: Past, Present, and Future.
Smith LM
Methods Mol Biol; 2022; 2500():1-4. PubMed ID: 35657582
[TBL] [Abstract][Full Text] [Related]
44. The Human Proteoform Atlas: a FAIR community resource for experimentally derived proteoforms.
Hollas MAR; Robey MT; Fellers RT; LeDuc RD; Thomas PM; Kelleher NL
Nucleic Acids Res; 2022 Jan; 50(D1):D526-D533. PubMed ID: 34986596
[TBL] [Abstract][Full Text] [Related]
45. Pituitary adenoma nitroproteomics: current status and perspectives.
Zhan X; Wang X; Desiderio DM
Oxid Med Cell Longev; 2013; 2013():580710. PubMed ID: 23533694
[TBL] [Abstract][Full Text] [Related]
46. Top-down proteomics: challenges, innovations, and applications in basic and clinical research.
Brown KA; Melby JA; Roberts DS; Ge Y
Expert Rev Proteomics; 2020 Oct; 17(10):719-733. PubMed ID: 33232185
[No Abstract] [Full Text] [Related]
47. Revealing Corynebacterium glutamicum proteoforms through top-down proteomics.
Melo RM; de Souza JMF; Williams TCR; Fontes W; de Sousa MV; Ricart CAO; do Vale LHF
Sci Rep; 2023 Feb; 13(1):2602. PubMed ID: 36788287
[TBL] [Abstract][Full Text] [Related]
48. How many human proteoforms are there?
Aebersold R; Agar JN; Amster IJ; Baker MS; Bertozzi CR; Boja ES; Costello CE; Cravatt BF; Fenselau C; Garcia BA; Ge Y; Gunawardena J; Hendrickson RC; Hergenrother PJ; Huber CG; Ivanov AR; Jensen ON; Jewett MC; Kelleher NL; Kiessling LL; Krogan NJ; Larsen MR; Loo JA; Ogorzalek Loo RR; Lundberg E; MacCoss MJ; Mallick P; Mootha VK; Mrksich M; Muir TW; Patrie SM; Pesavento JJ; Pitteri SJ; Rodriguez H; Saghatelian A; Sandoval W; Schlüter H; Sechi S; Slavoff SA; Smith LM; Snyder MP; Thomas PM; Uhlén M; Van Eyk JE; Vidal M; Walt DR; White FM; Williams ER; Wohlschlager T; Wysocki VH; Yates NA; Young NL; Zhang B
Nat Chem Biol; 2018 Feb; 14(3):206-214. PubMed ID: 29443976
[TBL] [Abstract][Full Text] [Related]
49. Mass spectrometry-based detection and assignment of protein posttranslational modifications.
Doll S; Burlingame AL
ACS Chem Biol; 2015 Jan; 10(1):63-71. PubMed ID: 25541750
[TBL] [Abstract][Full Text] [Related]
50. High sensitivity top-down proteomics captures single muscle cell heterogeneity in large proteoforms.
Melby JA; Brown KA; Gregorich ZR; Roberts DS; Chapman EA; Ehlers LE; Gao Z; Larson EJ; Jin Y; Lopez JR; Hartung J; Zhu Y; McIlwain SJ; Wang D; Guo W; Diffee GM; Ge Y
Proc Natl Acad Sci U S A; 2023 May; 120(19):e2222081120. PubMed ID: 37126723
[TBL] [Abstract][Full Text] [Related]
51. Proteomics of post-translational modifications in colorectal cancer: Discovery of new biomarkers.
Zhu G; Jin L; Sun W; Wang S; Liu N
Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188735. PubMed ID: 35577141
[TBL] [Abstract][Full Text] [Related]
52. Top-Down Proteomics and the Challenges of True Proteoform Characterization.
Po A; Eyers CE
J Proteome Res; 2023 Dec; 22(12):3663-3675. PubMed ID: 37937372
[TBL] [Abstract][Full Text] [Related]
53. Protein Language: Post-Translational Modifications Talking to Each Other.
Vu LD; Gevaert K; De Smet I
Trends Plant Sci; 2018 Dec; 23(12):1068-1080. PubMed ID: 30279071
[TBL] [Abstract][Full Text] [Related]
54. How can platelet proteomics best be used to interrogate disease?
Zellner M
Platelets; 2023 Dec; 34(1):2220046. PubMed ID: 37272536
[TBL] [Abstract][Full Text] [Related]
55. Post-translational modifications and mass spectrometry detection.
Silva AMN; Vitorino R; Domingues MRM; Spickett CM; Domingues P
Free Radic Biol Med; 2013 Dec; 65():925-941. PubMed ID: 24002012
[TBL] [Abstract][Full Text] [Related]
56. The first pilot project of the consortium for top-down proteomics: a status report.
Dang X; Scotcher J; Wu S; Chu RK; Tolić N; Ntai I; Thomas PM; Fellers RT; Early BP; Zheng Y; Durbin KR; Leduc RD; Wolff JJ; Thompson CJ; Pan J; Han J; Shaw JB; Salisbury JP; Easterling M; Borchers CH; Brodbelt JS; Agar JN; Paša-Tolić L; Kelleher NL; Young NL
Proteomics; 2014 May; 14(10):1130-40. PubMed ID: 24644084
[TBL] [Abstract][Full Text] [Related]
57. Comprehensive Protocol to Simultaneously Study Protein Phosphorylation, Acetylation, and N-Linked Sialylated Glycosylation.
Melo-Braga MN; Ibáñez-Vea M; Kulej K; Larsen MR
Methods Mol Biol; 2021; 2261():55-72. PubMed ID: 33420984
[TBL] [Abstract][Full Text] [Related]
58. Pituitary adenomas. An immunohistochemical study of hormone production and chromogranin localization.
DeStephano DB; Lloyd RV; Pike AM; Wilson BS
Am J Pathol; 1984 Sep; 116(3):464-72. PubMed ID: 6089568
[TBL] [Abstract][Full Text] [Related]
59. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].
Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV
Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157
[TBL] [Abstract][Full Text] [Related]
60. Defining the Sarcomeric Proteoform Landscape in Ischemic Cardiomyopathy by Top-Down Proteomics.
Chapman EA; Aballo TJ; Melby JA; Zhou T; Price SJ; Rossler KJ; Lei I; Tang PC; Ge Y
J Proteome Res; 2023 Mar; 22(3):931-941. PubMed ID: 36800490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
